Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05245201 · ClinicalTrials.gov registry record · NA

Clinical Decision Support for PrEP

A NA study of HIV Infections and Preexposure Prophylaxis (PrEP), sponsored by Harvard Pilgrim Health Care.

Active
Registry status
NA
Development phase
4
Enrollment target
3
Study locations

NCT05245201: Active NA study of HIV Infections and Preexposure Prophylaxis (PrEP), sponsored by Harvard Pilgrim Health Care.

NCT05245201 is a NA study of HIV Infections and Preexposure Prophylaxis (PrEP) that is active but no longer recruiting, run by Harvard Pilgrim Health Care. The registered enrollment target is 4 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05245201, a NA study of HIV Infections and Preexposure Prophylaxis (PrEP), is active but no longer recruiting, sponsored by Harvard Pilgrim Health Care.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
4 participants
Enrollment target
3
Study locations

Study Summary

Scale-up of HIV preexposure prophylaxis (PrEP) is a key strategy of the federal initiative to end the HIV epidemic. However, healthcare providers lack tools to identify patients who are at increased risk for HIV infection and thus likely to benefit from PrEP. This pilot study will test the hypothesis that an electronic health record (EHR)-based clinical decision support system that incorporates an HIV risk prediction model can help providers identify patients at increased risk for HIV infection and improve PrEP prescribing in safety-net community health centers. The clinical decision support system will be implemented in the EHR at 2-3intervention clinics, while 2 control clinics will receive standard of care. The primary outcome is PrEP prescriptions. Other key metrics of PrEP-related care to be assessed include medication persistence, adherence to monitoring guidelines for PrEP, and rates of HIV/STI testing and diagnoses. The expected outcome is the foundation for a large-scale cluster randomized trial to test whether EHR-based clinical decision support tools for PrEP can improve PrEP prescribing and prevent new HIV infections in a national network of community health centers.

Primary Outcome

Number of patients with increased predicted HIV risk who are prescribed PrEP

Conditions Studied

HIV Infections Preexposure Prophylaxis (PrEP)

Interventions

  • OTHER Standard of care
  • OTHER Clinical decision support for PrEP

Study Locations (3)

North Carolina

  • Roanoke Chowan Community Health Center - Ahoskie
  • Kintegra Health - Gastonia

California

  • Saban Community Clinic - Los Angeles

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2022-07-11
Est. Completion 2027-08
Phase NA
Harvard Pilgrim Health Care

28 total trials

What the registry record for NCT05245201 still lists

NCT05245201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT05245201 reports a single indexed study location in North Carolina, California.

Frequently Asked Questions

What is clinical trial NCT05245201 about?

NCT05245201 is a clinical study titled "Clinical Decision Support for PrEP". Scale-up of HIV preexposure prophylaxis (PrEP) is a key strategy of the federal initiative to end the HIV epidemic. However, healthcare providers lack tools to identify patients who are at increased risk for HIV infection and thus likely to benefit from PrEP. This pilot study will test the hypothesi...

What is the current status of trial NCT05245201?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 4 participants. The study started on 2022-07-11. Estimated completion is 2027-08.

What conditions does trial NCT05245201 study?

This clinical trial studies the following conditions: HIV Infections, Preexposure Prophylaxis (PrEP).

What interventions are being tested in trial NCT05245201?

The interventions under investigation include: Standard of care (OTHER), Clinical decision support for PrEP (OTHER).

Who is sponsoring clinical trial NCT05245201?

This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05245201 being conducted?

This trial has 3 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05245201's enrollment target sits among peer trials

4 541st of 542 higher than 2 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05245201, the US trial registry maintained by the National Library of Medicine. NCT05245201 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.